Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer
Source abstract
Abstract
The current clinical paradigm for ovarian cancer treatment has a poor prognosis, partially due to the efficacy and toxicity concerns associated with the available chemotherapeutic formulations. To overcome these limitations, we have designed core-shell-structured paclitaxel (PTX) laden solid lipid microparticles (PTX-SLMPs) for intraperitoneal treatment of ovarian cancer. A single-step coaxial electro hydrodynamic atomization (CEHDA) process has been explored to synthesize core-shell structure of PTX-SLMPs with the particle size of 1.76 ± 0.37 µm. Core-shell PTX-SLMPs have high encapsulation efficiency of 94.73% with sustained drug release profile. In vitro evaluation of PTX-SLMPs in SKOV-3 ovarian cancer cells yield significant enhancement in cytotoxicity when compared with Taxol®. In vivo pharmacokinetic study demonstrated slower absorption of PTX into the systemic circulation after intraperitoneal (i.p.) administration of PTX-SLMPs in Wistar rats implying the PTX-SLMPs remained in the peritoneal cavity and released the PTX for prolonged period of time. Through these studies, we have demonstrated the technical potential of core-shell structured PTX-SLMPs, which can enhance passive targeting of PTX to the tumor in the treatment of not only ovarian cancer but also in other peritoneal cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ovarian cancer diagnosis and treatment · Ovarian function and disorders · Reproductive Biology and Fertility
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Precision Machinery and Precision Instrumentation, School of Engineering Science, University of Science and Technology of China
Department of Chemistry, Laboratory of Nanomaterials for Energy Conversion (LNEC), University of Science and Technology of China
Division of Gynecologic Oncology, Ohio State University College of Medicine
Department of Biomedical Engineering, The Ohio State University
Funding
National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities
References (54)
Show source-provided references
1. Ovarian Cancer Overview. American Cancer Society. 2016.
2. 10.1056/NEJMra04184210.1056/NEJMra041842 ↗
3. 10.2353/ajpath.2010.10010510.2353/ajpath.2010.100105 ↗
4. 10.3322/caac.2138710.3322/caac.21387 ↗
5. 10.1093/jnci/djg03610.1093/jnci/djg036 ↗
6. 10.1097/CCO.0b013e32833ae99c10.1097/CCO.0b013e32833ae99c ↗
7. 10.1111/j.1525-1438.2007.01099.x10.1111/j.1525-1438.2007.01099.x ↗
8. 10.2147/CMAR.S3107010.2147/CMAR.S31070 ↗
9. Auersperg N, Edelson MI, Mok SC, et al. The biology of ovarian cancer. Semin Oncol. 1998;25:281–304.
10. 10.1097/00006254-197211000-0000110.1097/00006254-197211000-00001 ↗
11. 10.1016/j.ygyno.2007.10.00410.1016/j.ygyno.2007.10.004 ↗
12. 10.1155/2015/41307610.1155/2015/413076 ↗
13. 10.1016/j.ejps.2014.11.01210.1016/j.ejps.2014.11.012 ↗
14. 10.1016/j.ygyno.2017.04.01410.1016/j.ygyno.2017.04.014 ↗
15. 10.1016/j.ultsonch.2015.08.00910.1016/j.ultsonch.2015.08.009 ↗
16. 10.1016/j.canlet.2015.02.05210.1016/j.canlet.2015.02.052 ↗
17. 10.1517/17425247.2015.98081210.1517/17425247.2015.980812 ↗
18. 10.1016/j.ijpharm.2014.03.03610.1016/j.ijpharm.2014.03.036 ↗
19. 10.31083/ph.2011.006110.31083/ph.2011.0061 ↗
20. 10.1002/jps.2185410.1002/jps.21854 ↗
21. 10.1080/01932691.2010.50587610.1080/01932691.2010.505876 ↗
22. 10.1016/j.jconrel.2004.10.01110.1016/j.jconrel.2004.10.011 ↗
23. Yuan S, Lei F, Liu Z, et al. Coaxial electrospray of curcumin-loaded microparticles for sustained drug release. PLoS One. 2015;10:e0132609.
24. 10.1586/erd.12.5810.1586/erd.12.58 ↗
25. 10.1016/j.colsurfa.2018.03.01010.1016/j.colsurfa.2018.03.010 ↗
26. 10.1016/j.colsurfa.2016.10.03610.1016/j.colsurfa.2016.10.036 ↗
27. 10.1016/j.msec.2018.08.00410.1016/j.msec.2018.08.004 ↗
28. 10.1016/j.colsurfb.2013.11.04610.1016/j.colsurfb.2013.11.046 ↗
29. 10.1039/C6RA25314H10.1039/C6RA25314H ↗
30. 10.1016/j.cej.2015.09.05410.1016/j.cej.2015.09.054 ↗
31. 10.1021/acsami.7b0558010.1021/acsami.7b05580 ↗
32. 10.1016/j.ejps.2018.09.01610.1016/j.ejps.2018.09.016 ↗
33. 10.1016/j.jconrel.2011.05.01810.1016/j.jconrel.2011.05.018 ↗
34. 10.1021/acs.molpharmaceut.7b0086210.1021/acs.molpharmaceut.7b00862 ↗
35. 10.1080/1082607080192440210.1080/10826070801924402 ↗
36. 10.3109/1061186X.2012.72516910.3109/1061186X.2012.725169 ↗
37. 10.1016/j.jconrel.2014.12.00410.1016/j.jconrel.2014.12.004 ↗
38. 10.1016/j.addr.2009.07.01310.1016/j.addr.2009.07.013 ↗
39. 10.1021/ma501661610.1021/ma5016616 ↗
40. 10.1016/j.ijpharm.2006.11.03510.1016/j.ijpharm.2006.11.035 ↗
41. 10.1002/jbm.a.3286710.1002/jbm.a.32867 ↗
42. Singh MN, Hemant KSY, Ram M, et al. Microencapsulation: a promising technique for controlled drug delivery. Res Pharm Sci. 2010;5:65–77.
43. 10.1039/C5RA10642G10.1039/C5RA10642G ↗
44. 10.1016/j.ejpb.2016.08.00110.1016/j.ejpb.2016.08.001 ↗
45. 10.3109/10837450.2014.97137610.3109/10837450.2014.971376 ↗
46. 10.1016/j.ajps.2013.07.00110.1016/j.ajps.2013.07.001 ↗
47. 10.1016/j.tube.2010.12.00110.1016/j.tube.2010.12.001 ↗
48. 10.1021/ja409686x10.1021/ja409686x ↗
49. 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J ↗
50. 10.1016/S0304-3835(01)00404-910.1016/S0304-3835(01)00404-9 ↗
51. 10.1007/s11095-006-0022-210.1007/s11095-006-0022-2 ↗
52. 10.1007/s11095-007-9298-010.1007/s11095-007-9298-0 ↗
53. Dwivedi P, Yuan S, Han S, et al. Core-shell microencapsulation of curcumin in PLGA microparticles: programmed for application in ovarian cancer therapy. Artif Cells Nanomed Biotechnol. 2018;9:1–11.
54. 10.1016/j.nano.2016.04.01310.1016/j.nano.2016.04.013 ↗